Polyphron raises backing to build the verification substrate for AI drug discovery
darian314 · x · 2026-09-17
An investor announced backing for Polyphron, a startup building a "verification substrate" for biology. The thesis: AI models excel in strongly verifiable domains like math and code, and the team (Matthew Osman, FabioZB and co.) aims to bring that verifiability to drug discovery.
More from Venture
- Anthropic targets $1.5-2T IPO that could mint employee millionaires — but asks candidates what if stock hits zero — ArtificialOther · 2026-11-02
- Indie Dev's Founder Lifts Leaderboard Hits 101K Impressions After 2-Hour Build — denisyurchak · 2026-11-02
- Post Bridge Loses 20% of Customers Monthly; Founders Workshop the ICP Narrowing Dilemma Live — tibo_maker · 2026-11-02
- Enterprise AI's real game: getting companies to spend far more, not less — inductionheads · 2026-11-02
- Marvell and Lumentum to merge, targeting $550B AI connectivity market — BenBajarin · 2026-11-02
- OpenAI has raised less than half of its $30B target in latest funding round, WSJ reports — pstAsiatech · 2026-11-02